NasdaqGS - Nasdaq Real Time Price ? USD Enanta Pharmaceuticals, Inc. (ENTA) Follow Compare 11.11 +0.16 (+1.46%) At close: November 4 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders should be happy to see the share price up 16% in the last... Simply Wall St. ? 8 days ago ENTA +1.46% Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline We recently published a list of 7 Best Nano Cap Stocks To Invest In. In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against other best nano cap stocks to invest in. What Are the Small Cap Bulls Saying? In one of our recent articles about 8 Most […] Insider Monkey ? 16 days ago ENTA +1.46% Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares On September 30, 2024, Millennium Management LLC, a prominent hedge fund, expanded its investment portfolio by acquiring 73,1295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA). This transaction, executed at a price of $10.36 per share, marks a significant addition to the firm's holdings in the healthcare sector. The acquisition not only reflects Millennium's strategic investment approach but also highlights its confidence in Enanta Pharmaceuticals' future prospects. GuruFocus.com ? 18 days ago ENTA +1.46% Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. Zacks ? last month ENTA +1.46% BCRX J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration. BioPharma Dive ? last month ROG.SW ENTA +1.46% Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) WATERTOWN, Mass., September 26, 2024--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV Business Wire ? last month ENTA +1.46% Enanta Pharmaceuticals to Participate in Investor Conferences in September WATERTOWN, Mass., September 03, 2024--Enanta Pharmaceuticals to Participate in Investor Conferences in September Business Wire ? 2 months ago ENTA +1.46% Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now? We recently compiled a list of the Top 10 Holdings of Caligan Partners. In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against Caligan Partners’ other top holdings. Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds. David Johnson is the brainchild behind […] Insider Monkey ? 2 months ago ENTA +1.46% ^GSPC Enanta Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations Enanta Pharmaceuticals ( NASDAQ:ENTA ) Third Quarter 2024 Results Key Financial Results Revenue: US$18.0m (down 4.9... Simply Wall St. ? 2 months ago ENTA +1.46% Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 28.19% and 3.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago ENTA +1.46% Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot WATERTOWN, Mass. AP) — Enanta Pharmaceuticals Inc. ENTA) on Monday reported a loss of $22.7 million in its fiscal third quarter. Associated Press Finance ? 2 months ago ENTA +1.46% Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter WATERTOWN, Mass., August 05, 2024--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Business Wire ? 2 months ago ENTA +1.46% Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock? Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 3 months ago ENTA +1.46% ARDX Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference WATERTOWN, Mass., May 29, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY. Business Wire ? 5 months ago ENTA +1.46% Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags Enanta Pharmaceuticals ( NASDAQ:ENTA ) Second Quarter 2024 Results Key Financial Results Revenue: US$17.1m (down 4.2... Simply Wall St. ? 5 months ago ENTA +1.46% Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript May 6, 2024 Enanta Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Enanta Pharmaceuticals’ Fiscal Second Quarter Financial Results Conference Call. At this time, […] Insider Monkey ? 5 months ago ENTA +1.46% Q2 2024 Enanta Pharmaceuticals Inc Earnings Call Q2 2024 Enanta Pharmaceuticals Inc Earnings Call Thomson Reuters StreetEvents ? 5 months ago ENTA +1.46% Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference WATERTOWN, Mass., May 07, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY. Business Wire ? 5 months ago ENTA +1.46% Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ... Despite a net loss, ENTA progresses in RSV and immunology pipelines while maintaining a robust financial stance. GuruFocus.com ? 5 months ago ENTA +1.46% Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations Comparative Analysis Reveals Mixed Financial Outcomes GuruFocus.com ? 5 months ago ENTA +1.46% Performance Overview Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ENTA S&P 500 YTD +18.07% +19.77% 1-Year +18.57% +31.07% 3-Year -87.46% +22.57%
